PreTect AS

PreTect AS, based in Norway, specializes in research-based diagnostic testing solutions focused on enhancing cervical cancer prevention and management through advanced technologies. Founded in Norway, PreTect AS focuses on developing diagnostic tests for cervical cancer. The company has evolved its business strategy over time to prioritize high-risk HPV detection through innovative testing solutions. The headquarters is located in Oslo, Norway.

The current CEO is not mentioned in the available information. PreTect AS specializes in advanced diagnostic testing solutions aimed at enhancing cervical cancer prevention and management. Their core product offering, the PreTect HPV E6/E7 mRNA test, is designed to identify high-risk human papillomavirus (hrHPV) genotypes associated with cervical cancer, specifically focusing on mRNA markers from HPV types 16, 18, 31, 33, 45, 52, and 58. This test provides crucial information for clinicians in stratifying patient risk and determining the appropriate management steps, particularly for women in their twenties who are at risk of early cancer signs being overlooked.

By integrating their testing with traditional cytology methods, PreTect aims to improve the safety and efficacy of cervical cancer screening. Their services are provided through ISO13485 certified laboratories, serving healthcare providers and hospitals across Europe, with a focus on countries like Belgium, Norway, and other regions where cervical cancer screening and management are critical. PreTect AS operates a business model centered around B2B transactions, providing diagnostic testing services directly to healthcare institutions and pathology departments. The structure of these transactions typically involves healthcare providers ordering tests on behalf of patients, with results delivered in a timely manner to assist in clinical decision-making.

Revenue is generated from the sale of their flagship product, the PreTect HPV E6/E7 mRNA test, which is utilized in colposcopy referrals and patient management protocols. This approach allows clients to pay for testing services as needed, ensuring that healthcare providers can meet the demands of their patient populations effectively. The company emphasizes the importance of its services in addressing the urgent need for accurate cervical cancer risk assessment and management, thereby positioning itself as a critical partner in women's health initiatives. Future growth plans for PreTect AS include the development of new diagnostic products aimed at further enhancing cervical cancer screening effectiveness.

The company is exploring expansion into additional European markets, particularly targeting regions with rising cervical cancer rates by the end of 2024. Recent funding will be allocated to support the research and development of these new products, as well as marketing efforts to enter these new geographical areas.